THE MEANING OF THE MINIMAL RESIDUAL DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED DRUGS

被引：0

作者：

Kuvshinov, A. Yu ^{[1
]}

Voloshin, S. V. ^{[1
]}

Martynkevich, I. S. ^{[1
]}

Kleina, E., V ^{[1
]}

Chechetkin, A., V ^{[1
]}

机构：

[1] Russian Sci Res Inst Hematol & Transfusiol, St Petersburg 191024, Russia

来源：

GEMATOLOGIYA I TRANSFUZIOLOGIYA | 2016年 / 61卷 / 04期

关键词：

chronic lymphocytic leukemia; minimal residual disease; flow cytometry; ibrutinib; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; INITIAL THERAPY; ELDERLY-PATIENTS; YOUNGER PATIENTS; TREATMENT-NAIVE; FOLLOW-UP; IBRUTINIB; RITUXIMAB; IDELALISIB; REGIMEN;

D O I：

10.18821/0234-5730-2016-61-4-190-196

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the majority of patients with chronic lymphocytic leukemia (CLL) the complete remission (CR) and prolonged progression-free survival (PFS) can be achieved already after the first line chemoimmunotherapy. Nevertheless, a number of tumor cells (more than one per normal 10.000 cells) which determine the essence of minimal residual disease (MRD) is revealed by immunological and genetic methods in the bone marrow of significant number of patients in CR of the disease. MRD-negative status of a patient is associated with prolonged PFS and overall survival (OS) and being the only favorable prognostic factor determined after therapy. The delivery of targeted drugs for the therapy of in CLL (Ibrutinib, Idelalisib, Venclexta) possessing of high efficiency and low toxicity, give the hope to increase the number of MRD-negative remissions, and the change in treatment strategy for the solution of problems of control of residual tumor clone

引用

页码：190 / 196

页数：7

共 38 条

[1]

[Anonymous], BLOOD

[2] Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial [J].

Boettcher, Sebastian ;

Ritgen, Matthias ;

Fischer, Kirsten ;

Stilgenbauer, Stephan ;

Busch, Raymonde M. ;

Fingerle-Rowson, Guenter ;

Fink, Anna Maria ;

Buehler, Andreas ;

Zenz, Thorsten ;

Wenger, Michael Karl ;

Mendila, Myriam ;

Wendtner, Clemens-Martin ;

Eichhorst, Barbara F. ;

Doehner, Hartmut ;

Hallek, Michael J. ;

Kneba, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :980-988

[3] Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia:: High response rate and disease eradication [J].

Bosch, Francesc ;

Ferrer, Ana ;

Villamor, Neus ;

Gonzalez, Marcos ;

Briones, Javier ;

Gonzalez-Barca, Eva ;

Abella, Eugenia ;

Gardella, Santiago ;

Escoda, Lourdes ;

Perez-Ceballos, Elena ;

Asensi, Antoni ;

Jose Sayas, Ma ;

Font, Llorenc ;

Altes, Albert ;

Muntanola, Ana ;

Bertazzoni, Paola ;

Rozman, Maria ;

Aymerich, Marta ;

Gine, Eva ;

Montserrat, Ernili .

CLINICAL CANCER RESEARCH, 2008, 14 (01) :155-161

[4] Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation [J].

Böttcher, S ;

Ritgen, M ;

Pott, C ;

Brüggemann, M ;

Raff, T ;

Stilgenbauer, S ;

Döhner, H ;

Dreger, P ;

Kneba, M .

LEUKEMIA, 2004, 18 (10) :1637-1645

[5] Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia [J].

Brown, Jennifer R. ;

Byrd, John C. ;

Coutre, Steven E. ;

Benson, Don M. ;

Flinn, Ian W. ;

Wagner-Johnston, Nina D. ;

Spurgeon, Stephen E. ;

Kahl, Brad S. ;

Bello, Celeste ;

Webb, Heather K. ;

Johnson, Dave M. ;

Peterman, Sissy ;

Li, Daniel ;

Jahn, Thomas M. ;

Lannutti, Brian J. ;

Ulrich, Roger G. ;

Yu, Albert S. ;

Miller, Langdon L. ;

Furman, Richard R. .

BLOOD, 2014, 123 (22) :3390-3397

[6] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[7]

Busch R., 2014, BLOOD, V124, P19, DOI [10.1182/blood.V124.21.19.19, DOI 10.1182/BLOOD.V124.21.19.19]

[8] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[9] Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Shaw, Yun ;

Bilotti, Elizabeth ;

Zhou, Cathy ;

James, Danelle F. ;

O'Brien, Susan .

BLOOD, 2015, 125 (16) :2497-2506

[10] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

← 1 2 3 4 →